Sotyktu (deucravacitinib) is not a biologic. It is a small molecule drug taken as a daily pill, which places it in a fundamentally different category from biologic therapies like adalimumab (Humira) or ustekinumab (Stelara). This distinction matters because it affects how you take the medication, how it’s stored, and what the treatment experience feels like day to day.
Why Sotyktu Gets Confused With Biologics
The confusion makes sense. Sotyktu treats the same condition that biologics treat: moderate to severe plaque psoriasis. It works on the immune system, just as biologics do. And it was approved by the FDA in September 2022 as a systemic therapy, meaning it affects the whole body rather than just the skin’s surface. All of these features overlap with biologics.
But the chemistry is completely different. Biologics are large, complex proteins grown from living cells. They’re too fragile to survive the digestive system, so they have to be injected or infused. Sotyktu is a small, chemically synthesized molecule stable enough to be swallowed as a tablet. The FDA approved it at a dose of 6 mg taken orally once daily, with or without food. No injections, no infusion centers, no refrigeration.
How Sotyktu Works Differently
Sotyktu belongs to a new class of drug. It’s a selective TYK2 inhibitor, the first of its kind. TYK2 is an enzyme inside immune cells that helps relay inflammatory signals. When TYK2 is active, it triggers a chain reaction that ramps up inflammation in the skin. Sotyktu locks onto a specific part of the TYK2 enzyme and prevents it from switching on, which dials down the immune overreaction driving psoriasis plaques.
What makes Sotyktu unusual is where it binds. Rather than blocking the enzyme’s active site directly (the approach older drugs in the JAK inhibitor family use), it attaches to a regulatory region called the pseudokinase domain. This essentially keeps TYK2 stuck in its “off” position. The selectivity is striking: in lab testing across 249 different enzymes, deucravacitinib was highly specific to TYK2, which is part of why its safety profile looks different from broader JAK inhibitors.
Sotyktu vs. JAK Inhibitors and Safety
TYK2 is a member of the JAK family of enzymes, so Sotyktu is technically related to JAK inhibitors like tofacitinib. But the FDA treats it as a distinct drug class. Older JAK inhibitors that block multiple JAK enzymes carry a boxed warning (the FDA’s most serious safety alert) for increased risks of heart events, blood clots, cancer, and death, based on a large postmarketing trial in rheumatoid arthritis patients. Sotyktu does not carry a boxed warning. The FDA’s prescribing information notes that it is not yet known whether inhibiting TYK2 specifically carries the same risks seen with broader JAK inhibition.
How Well It Works Compared to Biologics
Sotyktu holds up well against some established biologics, particularly older ones. In an indirect comparison with adalimumab (Humira), the two treatments showed similar skin clearance rates at one year. By the two-year mark, Sotyktu pulled ahead: 67.2% of patients maintained at least 75% skin clearance with Sotyktu compared to 54% with adalimumab. The difference appeared because Sotyktu’s response rates held steady over time while adalimumab’s declined in the second year.
For more complete clearance (90% improvement), Sotyktu showed a numerical advantage at two years (41.3% vs. 34%), though this gap wasn’t large enough to be statistically conclusive. It’s worth noting these weren’t head-to-head trials but adjusted indirect comparisons, which are less definitive. Newer biologics targeting different immune pathways often achieve higher clearance rates than either Sotyktu or adalimumab.
What Side Effects Look Like
In the main clinical trials, about 53% to 58% of people taking Sotyktu reported at least one side effect during the first 16 weeks. That rate was similar to both the placebo groups (42% to 54%) and apremilast comparison groups (55% to 59%), suggesting most of these events were mild and would have occurred regardless of treatment.
The most common side effects were upper respiratory infections like colds and sore throats (nasopharyngitis in 6% to 11%, other upper respiratory infections in 5% to 6%), headache (4% to 5%), and diarrhea (4% to 5%). Serious adverse events were uncommon, occurring in about 2% of patients on Sotyktu. Only 2% to 3% of patients stopped taking the drug because of side effects, which was actually lower than the discontinuation rate in the placebo group.
In longer-term follow-up of over 1,200 patients, the side effect profile stayed consistent. The most commonly reported event in the extension period was COVID-19 (9%), reflecting the timing of the trials during the pandemic. Seven percent experienced a serious adverse event over the longer observation window, and only 2% stopped treatment.
The Practical Differences From Biologics
For many people, the biggest real-world distinction between Sotyktu and a biologic comes down to convenience. Biologics require injection or infusion, often need refrigeration, and may involve visits to a clinic. Sotyktu is a single small tablet taken once a day at room temperature. There are no needles, no special storage, and no scheduling around infusion appointments.
This also affects how quickly you can start or stop treatment. Biologic drugs linger in the body for weeks or months after you stop them because of their large molecular size. Small molecules like Sotyktu clear the body much faster, which gives you and your doctor more flexibility if you need to pause treatment for surgery or switch to something else.
Sotyktu does require routine blood work, particularly monitoring for changes in a muscle enzyme called creatine kinase. In trials, about 3% of patients on Sotyktu showed elevated levels, roughly in line with placebo rates. Your provider will likely check labs periodically but not with the same intensity required by some biologics or older JAK inhibitors.